Induced pluripotent stem cells: Will they be safe?

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 4, 2009, Pages 383-393

  Jalving, Mathilde ^a   Schepers, Hein ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cell therapy; Induced pluripotent stem cell; Malignant potential; Safety

Indexed keywords

ADENOVIRUS VECTOR; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2;

CARCINOGENICITY; CELL DIFFERENTIATION; CELL LINE; FIBROBLAST; GENE TRANSFER; HUMAN; INDUCED PLURIPOTENT STEM CELL; KERATINOCYTE; LIVER CELL; LYMPHOCYTE; NEURAL STEM CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PLURIPOTENT STEM CELL; REVIEW; SOMATIC CELL; TARGET CELL;

DATA COLLECTION; HUMANS; PLURIPOTENT STEM CELLS; SAFETY;

IPS;

EID: 68649125560     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Hochedlinger K, Jaenisch R: Nuclear reprogramming and pluripotency. Nature (2006) 441 (7097):1061-1067.
2. Nishikawa S, Goldstein RA, Nierras CR: The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol (2008) 9(9):725-729.
3. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 126(4):663-676.
4. Breakthrough article first describing the generation of iPS cells from mouse fibroblasts using four factors.
5. Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, Stadtfeld M, Yachechko R, Tchieu J, Jaenisch R, Plath K et al: Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell (2007) 1(1):55-70.
6. Okita K, Ichisaka T, Yamanaka S: Generation of germlinecompetent induced pluripotent stem cells. Nature (2007) 448 (7151):313-317.
7. Generation of the first germline-competent iPS cells is described. Tumors developed in 25% of chimeric mice.
8. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R: In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 448 (7151):318-324.
9. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 131(5):861-872.
10. First report of iPS cells generated from human somatic cells.
11. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II et al: Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 318 (5858):1917-1920.
12. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, Jaenisch R: Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science (2007) 318 (5858):1920-1923.
13. First proof-of-concept study in which mice with sickle cell anemia were transplanted using iPS cells generated from autologous skin, genetically modified and differentiated into hematopoietic cells.
14. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R: Neurons derived from reprogrammed fibroblasts functionally integrate into the fetalbrain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA (2008) 105(15): 5856-5861.
15. Nienhuis AW, Dunbar CE, Sorrentino BP: Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther (2006) 13(6): 1031-1049.
16. Yamanaka S: Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell (2007) 1(1):39-49.
17. Pera MF: Stem cells. A new year and a new era. Nature (2008) 451 (7175):135-136.
18. Maherali N, Hochedlinger K: Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell (2008) 3(6):595-605.
19. MEDLINE database: NIH, Bethesda, MD, USA (2009). www.pubmed.com
20. Cochrane database: Wiley, Hoboken, NJ, USA (2009). www3.interscience.wiley.com
21. EMBASE database: Elsevier, New York, NY, USA (2009). www.embase.com
22. Kim JB, Sebastiano V, Wu G, Araúzo-Bravo MJ, Sasse P, Gentile L, Ko K, Ruau D, Ehrich M, van den Boom D, Meyer J et al: Oct4-induced pluripotency in adult neural stem cells. Cell (2009) 136(3):411-419.
23. First paper to demonstrate that IPS cells can be generated using Oct-4 only.
24. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S: Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol (2008) 26(1):101-106.
25. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H et al: Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science (2008) 321 (5893):1218-1221.
26. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ: Disease-specific induced pluripotent stem cells. Cell (2008) 134(5):877-886.
27. Described the generation of a panel of disease-specific iPS cell lines.
28. Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, Chiba T, Yamanaka S: Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science (2008) 321 (5889):699-702.
29. Hanna J, Markoulaki S, Schorderet P, Carey BW, Beard C, Wernig M, Creyghton MP, Steine EJ, Cassady JP, Foreman R, Lengner CJ et al: Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell (2008) 133(2):250-264.
30. Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, Clark AT, Plath K: Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA (2008) 105(8):2883-2888.
31. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature (2008) 451 (7175):141-146.
32. Stadtfeld M, Brennand K, Hochedlinger K: Reprogramming of pancreatic β cells into induced pluripotent stem cells. Curr Biol (2008) 18(12):890-894.
33. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K: Induced pluripotent stem cells generated without viral integration. Science (2008) 322 (5903):945-949.
34. Eminli S, Utikal J, Arnold K, Jaenisch R, Hochedlinger K: Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells (2008) 26(10):2467-2474.
35. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK et al: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell (2005) 122(6):947-956.
36. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J, Wong KY et al: The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet (2006) 38(4):431-440.
37. Hochedlinger K, Yamada Y, Beard C, Jaenisch R: Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell (2005) 121(3):465-477.
38. Gidekel S, Pizov G, Bergman Y, Pikarsky E: Oct-3/4 is a dosedependent oncogenic fate determinant. Cancer Cell (2003) 4(5):361-370.
39. Sotomayor P, Godoy A, Smith GJ, Huss WJ: Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate (2009) 69(4):401-410.
40. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B: Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun (2009) 383(2):157-162.
41. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R: Multipotent cell lineages in early mouse development depend on Sox2 function. Genes Dev (2003) 17(1):126-140.
42. Li M, Pevny L, Lovell-Badge R, Smith A: Generation of purified neural precursors from embryonic stem cells by lineage selection. Curr Biol (1998) 8(17):971-974.
43. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G: SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells (2009) 27(1):40-48.
44. Gu G, Yuan J, Wills M, Kasper S: Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res (2007) 67(10):4807-4815.
45. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J: Sox2: A possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol (2007) 20(4):474-481.
46. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 40(5):499-507.
47. Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE, Ruppert JM: Increase of gKlf messenger RNA and protein expression during progression of breast cancer. Cancer Res (2000) 60(22):6488-6495.
48. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, Kudlow JE et al: Induction of Klf4 in basal keratinocytes blocks the proliferationdifferentiation switch and initiates squamous epithelial dysplasia. Oncogene (2005) 24(9):1491-1500.
49. Rowland BD, Bernards R, Peeper DS: The Klf4 tumour suppressor is a transcriptional repressor of p53 that acts as a contextdependent oncogene. Nat Cell Biol (2005) 7(11):1074-1082.
50. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, Xu Y: p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol (2005) 7(2): 165-171.
51. Huang CC, Liu Z, Li X, Bailey SK, Nail CD, Foster KW, Frost AR, Ruppert JM, Lobo-Ruppert SM: Klf4 and PCNA identify stages of tumor initiation in a conditional model of cutaneous squamous epithelial neoplasia. Cancer Biol Ther (2005) 4(12):1401-1408.
52. Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H, Bland KI et al: Nuclear localization of Klf4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res (2004) 10(8):2709-2719.
53. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B: Genomic targets of the human c-Myc protein. Genes Dev (2003) 17(9):1115-1129.
54. Marion RM, Strati K, Li H, Tejera A, Schoeftner S, Ortega S, Serrano M, Blasco MA: Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell (2009) 4(2):141-154.
55. Miura T, Katakura Y, Yamamoto K, Uehara N, Tsuchiya T, Kim EH, Shirahata S: Neural stem cells lose telomerase activity upon differentiating into astrocytes. Cytotechnology (2001) 36 (1-3) :137-144.
56. Wernig M, Meissner A, Cassady JP, Jaenisch R: c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell (2008) 2(1):10-12.
57. Pera MF, Hasegawa K: Simpler and safer cell reprogramming. Nat Biotechnol (2008) 26(1):59-60.
58. Blelloch R, Venere M, Yen J, Ramalho-Santos M: Generation of induced pluripotent stem cells in the absence of drug selection. Cell Stem Cell (2007) 1(3):245-247.
59. Brambrink T, Foreman R, Welstead GG, Lengner CJ, Wernig M, Suh H, Jaenisch R: Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell (2008) 2(2):151-159.
60. Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K: A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell (2008) 3 (3):340-345.
61. Stadtfeld M, Maherali N, Breault DT, Hochedlinger K: Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell (2008) 2(3):230-240.
62. Hawley RG: Does retroviral insertional mutagenesis play a role in the generation of induced pluripotent stem cells? Mol Ther (2008) 16(8):1354-1355.
63. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R et al: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302 (5644):415-419.
64. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O: Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell (2009) 136(5):964-977.
65. Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, Mitalipova M, Jaenisch R: Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci USA (2009) 106(1):157-162.
66. Smith RH: Adeno-associated virus integration: virus versus vector. Gene Ther (2008) 15(11):817-22.
67. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA: Human induced pluripotent stem cells free of vector and transgene sequences. Science (2009) 324 (5928): 797-801.
68. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, Cowling R, Wang W, Liu P, Gertsenstein M, Kaji K et al: PiggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature (2009) 458 (7239): 766-770.
69. Wilson MH, Coates CJ, George Al Jr: PiggyBac transposon-mediated gene transfer in human cells. Mol Ther (2007) 15(1):139-145.
70. Yusa K, Rad R, Takeda J, Bradley A: Generation of transgenefree induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods (2009) 6(5):363-369.
71. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S: Generation of mouse induced pluripotent stem cells without viral vectors. Science (2008) 322 (5903):949-953.
72. Describes the generation of iPS cells using plasmid transfection, and demonstrates that alternatives to the use of viral vectors exist.
73. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA: Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol (2008) 26(7):795- 797.
74. Demonstrated that small molecules can increase the efficiencies of pluripotent cell induction.
75. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G et al: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell (2009) 4(5):381-384.
76. First study to demonstrate that iPS cells can be generated without introducing exogenous genetic sequences, bringing the use of iPS cells closer to clinical applications.
77. Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young RA, Jaenisch R: Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell (2008) 3(2): 132-135.
78. Mikkelsen TS, Hanna J, Zhang X, Ku M, Wernig M, Schorderet P, Bernstein BE, Jaenisch R, Lander ES, Meissner A: Dissecting direct reprogramming through integrative genomic analysis. Nature (2008) 454 (7200):49-55.
79. Shi Y, Do JT, Desponts C, Hahm HS, Schöler HR, Ding S: A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell (2008) 2(6): 525-528.
80. Ruau D, Ensenat-Waser R, Dinger TC, Vallabhapurapu DS, Rolletschek A, Hacker C, Hieronymus T, Wobus AM, Müller AM, Zenke M: Pluripotency associated genes are reactivated by chromatin-modifying agents in neurosphere cells. Stem Cells (2008) 26(4):920-926.
81. Sridharan R, Tchieu J, Mason MJ, Yachechko R, Kuoy E, Horvath S, Zhou Q, Plath K: Role of the murine reprogramming factors in the induction of pluripotency. Cell (2009) 136(2):364-377.
82. Jaenisch R, Young R: Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell (2008) 132(4):567-582.
83. Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, Beighton G, Bello PA, Benvenisty N, Berry LS, Bevan S, Blum B et al: Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol (2007) 25(7):803-816.
84. Knoepfer PS: Deconstructing stem cell tumorigenicity: A roadmap to safe regenerative medicine. Stem Cells (2009) 27(5):1050-1056.
85. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson M, Smart NG, Cunningham J, Agulnick AD et al: Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol (2008) 26(4):443-452.
86. Amabile G, Meissner A: Induced pluripotent stem cells: Current progress and potential for regenerative medicine. Trends Mol Med (2009) 15(2):59-68.
87. Choo AB, Tan HL, Ang SN, Fong WJ, Chin A, Lo J, Zheng L, Hentze H, Philp RJ, Oh SK, Yap M: Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells (2008) 26(6):1454-1463.
88. Schuldiner M, Itskovitz-Eldor J, Benvenisty N: Selective ablation of human embryonic stem cells expressing a 'suicide' gene. Stem Cells (2003) 21(3):257-265.